

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 03/044056 A2

- (51) International Patent Classification⁷: **C07K 14/61**, A61K 47/48, 38/27
- (74) Agents: **BAUER, Christopher, S. et al.**; Pharmacia Corporation, Corporate Patent Department, 800 North Lindbergh Blvd., Mailzone O4E, St Louis, MO 63167 (US).
- (21) International Application Number: **PCT/US02/37270**
- (22) International Filing Date:
20 November 2002 (20.11.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/331,907 20 November 2001 (20.11.2001) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **PHARMACIA CORPORATION** [US/US]; Corporate Patent Dept., 800 N. Lindbergh Boulevard, Mail Zone O4E, St. Louis, MO 63167 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **FINN, Rory, F.** [US/US]; 976 Sunnburst Ct., Manchester, MO 63021 (US). **LAO, Wei** [CN/US]; 17143 Hillcrest Meadow Drive, Chesterfield, MO 63005 (US). **SIEGEL, Ned, R.** [US/US]; 312 North Powder Mill Rd., Belleville, IL 62223 (US).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **CHEMICALLY-MODIFIED HUMAN GROWTH HORMONE CONJUGATES**

(57) Abstract: The present invention provides a chemically modified human Growth Hormone (hGH) prepared by binding a water soluble polymer to the protein. The chemically-modified protein according to the present invention may have a much longer lasting hGH activity than that of the unmodified hGH, enabling reduced dose and scheduling opportunities.

WO 03/044056 A2

CHEMICALLY-MODIFIED HUMAN GROWTH HORMONE CONJUGATES

The present application claims priority under Title
5 35, United States Code, §119 to United States
Provisional application Serial No. 60/331,907, filed
November 20, 2001, which is incorporated by reference
in their entirety as if written herein.

10 FIELD OF THE INVENTION

The present invention relates to a chemical
modification of human Growth Hormone (hGH) and agonist
variants thereof by which the chemical and/or
15 physiological properties of hGH can be changed. The
PEGylated hGH may have an increased plasma residency
duration, decreased clearance rate, improved
stability, decreased antigenicity, or a combination
thereof. The present invention also relates to
20 processes for the modification of hGH. In addition,
the present invention relates to pharmaceutical
compositions comprising the modified hGH. A further
embodiment is the use of the modified hGH for the
treatment of growth and development disorders.

25

BACKGROUND OF THE INVENTION

Human growth hormone (hGH) is a protein
30 comprising a single chain of 191 amino acids cross-
linked by two disulphide bridges and the monomeric
form has a molecular weight of 22 kDa. Human GH is
secreted by the pituitary gland and which also can be
produced by recombinant genetic engineering. hGH will
35 cause growth in all bodily tissues that are capable of

growth. Recombinant hGH has been commercially available for several years. Two types of therapeutically useful recombinant hGH preparations are present on the market: the authentic one, e.g. Genotropin™, or Nutropin™ and an analogue with an additional methionine residue at the N-terminal end, e.g. Somatonorm™. hGH is used to stimulate linear growth in patients with hypo pituitary dwarfism also referred to as Growth Hormone Deficiency (GHD) or Turner's syndrome but other indications have also been suggested including long-term treatment of growth failure in children who were born short for gestational age (SGA), for treatment of patients with Prader-Willi syndrome (PWS), chronic renal insufficiency (CRI), Aids wasting, and Aging.

A major biological effect of growth hormone (GH) is to promote growth in young mammals and maintenance of tissues in older mammals. The organ systems affected include the skeleton, connective tissue, muscles, and viscera such as liver, intestine, and kidneys. Growth hormones exert their effect through interaction with specific receptors on the target cell's membrane. hGH is a member of a family of homologous hormones that include placental lactogens, prolactins, and other genetic and species variants or growth hormone (Nicoll, C. S., et al. (1986) *Endocrine Reviews* 7: 169). hGH is unusual among these in that it exhibits broad species specificity and binds to either the cloned somatogenic (Leung, D. W., et al. [1987] *Nature* 330; 537) or prolactin receptor (Boutin, J. M., et al. [1988] *Cell*; 53: 69). The cloned gene for hGH has been expressed in a secreted form in *Escherichia coli* (Chang, C. N., et al. [1987] *Gene* 55:189), and its DNA and amino acid sequence has been reported

(Goeddel, et al. [1979] *Nature* 281: 544; Gray, et al. [1985] *Gene* 39:247).

Human growth hormone (hGH) participates in much
5 of the regulation of normal human growth and
development. This pituitary hormone exhibits a
multitude of biological effects including linear
growth (somatogenesis), lactation, activation of
macrophages, insulin-like and diabetogenic effects
10 among others (Chawla, R. K. (1983) *Ann. Rev. Med.* 34,
519; Edwards, C. K. et al. (1988) *Science* 239, 769;
Thomer, M. O., et al. (1988) *J. Clin. Invest.* 81:745).
Growth hormone deficiency in children leads to
dwarfism, which has been successfully treated for more
15 than a decade by exogenous administration of hGH.

Human growth hormone (hGH) is a single-chain
polypeptide consisting of 191 amino acids (molecular
weight 21,500). Disulfide bonds link positions 53 and
20 165 and positions 182 and 189. Niall, *Nature, New
Biology*, 230:90 (1971). hGH is a potent anabolic
agent, especially due to retention of nitrogen,
phosphorus, potassium, and calcium. Treatment of
hypophysectomized rats with GH can restore at least a
25 portion of the growth rate of the rats. Moore et al.,
Endocrinology 122:2920-2926 (1988). Among its most
striking effects in hypo pituitary (GH-deficient)
subjects is accelerated linear growth of bone-growth-
plate-cartilage resulting in increased stature.
30 Kaplan, *Growth Disorders in Children and Adolescents*
(Springfield, IL: Charles C. Thomas, 1964).

hGH causes a variety of physiological and
metabolic effects in various animal models including
35 linear bone growth, lactation, activation of

macrophages, insulin-like and diabetogenic effects, and others (R. K. Chawla et al., *Annu. Rev. Med.* 34:519 (1983); O. G. P. Isaksson et al., *Annu. Rev. Physiol.* 47, 483 (1985); C. K. Edwards et al., *Science* 5 239, 769 (1988); M. O. Thomer and M. L. Vance, *J. Clin. Invest.* 82:745 (1988); J. P. Hughes and H. G. Friesen, *Ann. Rev. Physiol.* 47:469 (1985)). It has been reported that, especially in women after menopause, GH secretion declines with age. Millard et al., *Neurobiol. Aging*, 11:229-235 (1990); Takahashi et al., *Neuroendocrinology* M, L6- 137-142 (1987). See also Rudman et al., *J. Clin. Invest.*, 67:1361-1369 (1981) and Blackman, *Endocrinology and Aging*, 16:981 (1987). Moreover, a report exists that some of the 15 manifestations of aging, including decreased lean body mass, expansion of adipose-tissue mass, and the thinning of the skin, can be reduced by GH treatment three times a week. See, e.g., Rudman et al., *N. Eng. J. Med.*, 323:1-6 (1990) and the accompanying article 20 in the same journal issue by Dr. Vance (pp. 52-54). These biological effects derive from the interaction between hGH and specific cellular receptors. Two different human receptors have been cloned, the hGH liver receptor (D. W. Leung et al., *Nature* 25 330:537(1987)) and the human prolactin receptor (J. M. Boutin et al., *Mol. Endocrinology.* 3:1455 (1989)). However, there are likely to be others including the human placental lactogen receptor (M. Freemark, M. Comer, G. Komer, and S. Handwerger, *Endocrinol.* 30 120:1865 (1987)). These homologous receptors contain a glycosylated extracellular hormone binding domain, a single transmembrane domain, and a cytoplasmic domain, which differs considerably in sequence and size. One or more receptors are assumed to play a determining 35 role in the physiological response to hGH.

It is generally observed that physiologically active proteins administered into a body can show their pharmacological activity only for a short period of time due to their high clearance rate in the body.

5 Furthermore, the relative hydrophobicity of these proteins may limit their stability and/or solubility.

For the purpose of decreasing the clearance rate, improving stability or abolishing antigenicity of therapeutic proteins, some methods have been proposed
10 wherein the proteins are chemically modified with water-soluble polymers. Chemical modification of this type may block effectively a proteolytic enzyme from physical contact with the protein backbone itself, thus preventing degradation. Chemical attachment of
15 certain water-soluble polymers may effectively reduce renal clearance due to increased hydrodynamic volume of the molecule. Additional advantages include, under certain circumstances, increasing the stability and circulation time of the therapeutic protein,
20 increasing solubility, and decreasing immunogenicity. Poly(alkylene oxide), notably poly(ethylene glycol) (PEG), is one such chemical moiety that has been used in the preparation of therapeutic protein products (the verb "pegylate" meaning to attach at least one
25 PEG molecule). The attachment of poly(ethylene glycol) has been shown to protect against proteolysis, Sada, et al., *J. Fermentation Bioengineering* 71: 137-139 (1991), and methods for attachment of certain poly(ethylene glycol) moieties are available. See U.S.
30 Pat. No. 4,179,337, Davis et al., "Non-Immunogenic Polypeptides," issued Dec. 18, 1979; and U.S. Pat. No. 4,002,531, Royer, "Modifying enzymes with Polyethylene Glycol and Product Produced Thereby," issued Jan. 11, 1977. For a review, see Abuchowski et al., in Enzymes

as Drugs. (J. S. Holcerberg and J. Roberts, eds. pp. 367-383 (1981)).

Other water-soluble polymers have been used, such as copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, poly(vinyl alcohol), poly(vinyl pyrrolidone), poly(-1,3-dioxolane), poly(-1,3,6-trioxane), ethylene/maleic anhydride copolymer, poly- amino acids (either homopolymers or random copolymers).

10

A number of examples of pegylated therapeutic proteins have been described. ADAGEN®, a pegylated formulation of adenosine deaminase, is approved for treating severe combined immunodeficiency disease.

15 ONCASPAR®, a pegylated L-asparaginase has been approved for treating hypersensitive ALL patients. Pegylated superoxide dismutase has been in clinical trials for treating head injury. Pegylated α -interferon (U.S. 5,738,846, 5,382,657) has been
20 approved for treating hepatitis; pegylated glucocerebrosidase and pegylated hemoglobin are reported to have been in preclinical testing. Another example is pegylated IL-6, EF 0 442 724, entitled, "Modified hIL-6," which discloses poly(ethylene
25 glycol) molecules added to IL-6.

Another specific therapeutic protein, which has been chemically modified, is granulocyte colony stimulating factor, (G-CSF). G-CSF induces the rapid proliferation and release of neutrophilic granulocytes
30 to the blood stream, and thereby provides therapeutic effect in fighting infection. European patent publication EP 0 401 384, published Dec. 12, 1990, entitled, "Chemically Modified Granulocyte Colony Stimulating Factor," describes materials and methods
35 for preparing G-CSF to which poly(ethylene glycol)

molecules are attached. Modified G-CSF and analogs thereof are also reported in EP 0 473 268, published Mar. 4, 1992, entitled "Continuous Release Pharmaceutical Compositions Comprising a Polypeptide Covalently Conjugated To A Water Soluble Polymer," stating the use of various G-CSF and derivatives covalently conjugated to a water soluble particle polymer, such as poly(ethylene glycol). A modified polypeptide having human granulocyte colony stimulating factor activity is reported in EP 0 335 423 published Oct. 4, 1989. Provided in U.S. 5,824,784 are methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions. U.S. 5,824,778 discloses chemically modified G-CSF.

For poly(ethylene glycol), a variety of means have been used to attach the poly(ethylene glycol) molecules to the protein. Generally, poly(ethylene glycol) molecules are connected to the protein via a reactive group found on the protein.

Amino groups, such as those on lysine residues or at the N-terminus, are convenient for such attachment. For example, Royer (U.S. Pat. No. 4,002,531, above) states that reductive alkylation was used for attachment of poly(ethylene glycol) molecules to an enzyme. EP 0 539 167, published Apr. 28, 1993, Wright, "Peg Imidates and Protein Derivatives Thereof" states that peptides and organic compounds with free amino group(s) are modified with an imidate derivative of PEG or related water-soluble organic polymers. US 5,298,643 and US 5,637,749 disclose PEG aryl imidates

Chamow et al., *Bioconjugate Chem.* 5: 133-140 (1994) report the modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via

reductive alkylation. The authors report that 50% of the CD4-Ig was MePEG-modified under conditions allowing control over the extent of pegylation. *Id.* at page 137. The authors also report that the *in vitro*
5 binding capability of the modified CD4-Ig (to the protein gp 120) decreased at a rate correlated to the extent of MePEGylation *Ibid.* U.S. Pat. No. 4,904,584, Shaw, issued Feb. 27, 1990, relates to the modification of the number of lysine residues in
10 proteins for the attachment of poly(ethylene glycol) molecules via reactive amine groups.

Many methods of attaching a polymer to a protein involve using a moiety to act as a linking group. Such moieties may, however, be antigenic. A tresyl
15 chloride method involving no linking group is available, but this method may be difficult to use to produce therapeutic products as the use of tresyl chloride may produce toxic by-products. See Francis et al., In: Stability of protein pharmaceuticals: in vivo
20 pathways of degradation and strategies for protein stabilization (Eds. Ahern, T. and Manning, M. C.) Plenum, New York, 1991) Also, Delgado et al., "Coupling of PEG to Protein By Activation With Tresyl Chloride, Applications In Immunoaffinity Cell
25 Preparation", in Separations Using Aqueous Phase Systems, Applications In Cell Biology and Biotechnology, Fisher et al., eds. Plenum Press, New York, N.Y., 1989 pp. 211-213.

See also, Rose et al., *Bioconjugate Chemistry* 2: 30 154-159 (1991) which reports the selective attachment of the linker group carbonyldrazide to the C-terminal carboxyl group of a protein substrate (insulin).

WO 93/00109 relates to a method for stimulating a mammal's or avian's GH responsive tissues comprising
35 maintaining a continuous, effective plasma GH

concentration for a period of 3 or more days. One way of achieving such plasma concentration is stated to be by use of GH coupled to a macromolecular substance such as PEG (polyethylene glycol). The coupling to a macromolecular substance is stated to result in improved half-life. PEGylated human growth hormone has been reported in WO 93/00109 using mPEG aldehyde-5000 and mPEG N-hydroxysuccinimidyl ester (mPEG-NHS-5000). The use of mPEG-NHS resulted in heterogeneous mixtures of multiply PEGylated forms of hGH. WO 93/00109 also discloses the use of mPEG-maleimide to PEGylate cysteine hGH variants.

WO 99/03887 discloses a cysteine variant growth hormone that is PEGylated. Designated as BT-005, this conjugate is purported to be more effective at stimulating weight gain in growth hormone deficient rats and to have a longer half-life than hGH.

PEGylated human growth hormone has also been reported in Clark et al. using succinimidyl ester of carboxymethylated PEG (*Journal of Biological Chemistry* 271:21969-21977, 1996). Clark et al. describes derivatives of hGH of increasing size using mPEG-NHS-5000, which selectively conjugates to primary amines. Increasing levels of PEG modification reduced the affinity for its receptor and increased the EC₅₀ in a cell-based assay up to 1500 fold. Olson et al., *Polymer Preprints* 38:568-569, 1997 discloses the use of N-hydroxysuccinimide (NHS) PEG and succinimidyl propionate (SPA) PEG to achieve multiply PEGylated hGH species.

WO 94/20069 prophetically discloses PEGylated hGH as part of a formulation for pulmonary delivery.

US 4,179,337 discloses methods of PEGylating

enzymes and hormones to obtain physiologically active non-immunogenic, water-soluble polypeptide conjugates. GH is mentioned as one example of a hormone to be PEGylated.

5

EP 458064 A2 discloses PEGylation of introduced or naturally present cysteine residues in somatotropin. EP 458064 A2 further mentions the incorporation of two cysteine residues in a loop
10 termed the omega loop stated to be located at residues 102-112 in wild type bovine somatotropin, more specifically EP 458064 A2 discloses the substitution of residues numbered 102 and 112 of bovine somatotropin from Ser to Cys and Tyr to Cys,
15 respectively.

WO 95/11987 suggests attachment of PEG to the thiol group of a cysteine residue being either present in the parent molecule or introduced by site directed
20 mutagenesis. WO 95/11987 relates to PEGylation of protease nexin-1, however PEGylation in general of hGH and other proteins is suggested as well.

WO 99/03887 discloses, e.g., growth hormone
25 modified by insertion of additional cysteine for serine residues and attachment of PEG to the introduced cysteine residues.

WO 00/42175 relates to a method for making
30 proteins containing free cysteine residues for attachment of PEG. WO 00/42175 discloses the following muteins of hGH: T3C, S144C and T148C and the cysteine PEGylation thereof.

35 WO 9711178 (as well as US 5849535, US 6004931,

and US 6022711) relates to the use of GH variants as agonists or antagonists of hGH. WO 9711178 also discloses PEGylation of hGH, including lysine PEGylation and the introduction or replacement of
5 lysine (e.g. K168A and K172R). WO 9711178 also discloses the substitution G120K.

The previous reports of PEGylated hGH require the attachment of multiple PEGs, which results in
10 undesirable product heterogeneity, to achieve a hydrodynamic volume greater than the 70K molecular weight cut-off of the kidney filtration as described (Knauf, M.J. et al, *J. Biol. Chem.* 263:15064-15070,1988).

15

A GH molecule with a longer circulation half-life would decrease the number of necessary administrations and potentially provide more optimal therapeutic hGH levels with concomitant enhanced therapeutic effect.

20

The present invention provides chemically modified hGH conjugates having decreased heterogeneity, decreased clearance rate, increased plasma residency duration, improved solubility,
25 increased stability, decreased antigenicity, or combinations thereof.

SUMMARY OF THE INVENTION

30

The present invention relates to chemically modified hGH and agonist variants thereof, which have at least one improved chemical or physiological property selected from but not limited to decreased
35 clearance rate, increased plasma residency duration,

increased stability, improved solubility, and decreased antigenicity. Thus, as described below in more detail, the present invention has a number of aspects relating to chemically modifying hGH and
5 agonist variants thereof as well as specific modifications using a variety of poly(ethylene glycol) moieties.

The present invention also relates to methods of producing the chemically modified hGH and agonist
10 variants thereof.

The present invention also relates to compositions comprising the chemically modified hGH and agonist variants thereof.

The modified hGH and agonist variants thereof of
15 the present invention may be useful in the treatment of, but not limited to, dwarfism (GHD), Adult GHD, Turner's syndrome, long-term treatment of growth failure in children who were born short for gestational age (SGA), for treatment of patients with
20 Prader-Willi syndrome (PWS), chronic renal insufficiency (CRI), Aids wasting, Aging, End-stage Renal Failure, and Cystic Fibrosis.

BRIEF DESCRIPTION OF THE DRAWINGS

25

Figure 1 is a reproduction of a reducing and non-reducing SDS-PAGE analysis of the products of the reaction of hGH and 20K PEG-ALD and the anion exchange purified 20K PEG-ALD hGH. Lane 1. MW Protein
30 standards; Lane 2. reduced hGH-10 ug; Lane 3. reduced 20 K linear PEG-ALD hGH reaction mix-10 ug; Lane 4. reduced anion exchange purified 20 K linear PEG-ALD hGH-10 ug Lane 5. Blank; Lane 6. non-reduced hGH-10 ug; Lane 7. non-reduced 20 K linear PEG-ALD hGH
35 reaction mix-10 ug; Lane 8. non-reduced anion

exchange purified 20 K linear PEG-ALD hGH-10 ug; Lane 9. Blank; Lane 10. MW Protein standards.

Figure 2 is a reproduction of a non-reducing SDS-PAGE analysis of various anion exchange purified pegylated hGH molecules. Lane 1. MW Protein standards; Lane 2. hGH-10 ug; Lane 2. 4-6 x 5K PEG-SPA hGH-10 ug; Lane 3. 20 K linear PEG-ALD hGH-10 ug; Lane 4. 20 K branched PEG-ALD hGH-10 ug Lane 5. 40 K branched PEG hGH-10 ug.

Figure 3 shows reproductions of RP-HPLC elution profiles for trypsin digests of hGH, 40K Br PEG-ALD hGH and 40K Br PEG-NHS hGH. PEG coupled primarily to the N-terminus of hGH (as shown in the 40K Br ALD hGH) results in a reduction in the N-terminal (T1) fragment peak with generation of a new PEGylated T1 peak.

Figure 4 compares the *in vivo* bioactivity of unPEGylated hGH dosed daily (0.3 mg/Kg/day) to mono-PEGylated hGH dosed subcutaneously(SC) once every six days(1.8 mg/Kg) by illustrating the weight gain in hypophysectomized rats during a period of 11 days.

Figure 5 compares the *in vivo* bioactivity of unPEGylated hGH dosed SC daily (0.3 mg/Kg/day) to 4-6 x 5K PEG-SPA-hGH, mono-PEGylated 20K branched PEG-ALD hGH, and mono-PEGylated 40K branched PEG-ALD hGH each dosed SC once every six days (1.8 mg/Kg) by illustrating the weight gain in hypophysectomized rats during a period of 11 days.

Figure 6 compares the *in vivo* bioactivity of unPEGylated hGH dosed SC daily (0.3 mg/Kg/day) to 4-6 x 5K PEG-CMHBA-hGH, mono-PEGylated 20K linear ALD,

mono-PEGylated 30K linear ALD, mono-PEGylated 20K
branched PEG-ALD hGH, and mono-PEGylated 40K branched
PEG-ALD hGH each dosed SC once every six days (1.8
mg/Kg) by illustrating the increase in tibial bone
5 growth in hypophysectomized rats during a period of 11
days.

Figure 7 compares the *in vivo* bioactivity of a single
1.8 mg/Kg SC dose of unPEGylated hGH, mono-PEGylated
10 5K linear PEG-ALD hGH, mono-PEGylated 20K linear PEG-
ALD hGH, mono-PEGylated 20K branched PEG-ALD hGH,
mono-PEGylated 20K linear PEG-Hydrazide hGH, mono-
PEGylated 30K linear PEG-ALD hGH, mono-PEGylated 40K
branched PEG-ALD hGH, 4-6 x 5K PEG SPA hGH, 4-6 x 5K
15 PEG-CMHBA hGH by illustrating the increase in plasma
IGF-1 levels in hypophysectomized rats during a period
of 9 days.

DETAILED DESCRIPTION

20

hGH and agonist variants thereof are members of a
family of recombinant proteins, described in US
4,658,021 and US 5,633,352. Their recombinant
production and methods of use are detailed in US
25 4,342,832, 4,601,980; US 4,898,830; US 5,424,199; and
US 5,795,745.

Any purified and isolated hGH or agonist variant
thereof, which is produced by host cells such as *E.*
coli and animal cells transformed or transfected by
30 using recombinant genetic techniques, may be used in
the present invention. Additional hGH variants are
described in U.S. Ser. No. 07/715,300 filed Jun.14,
1991 and Ser. No. 07/743,614 filed Aug. 9, 1991, and
WO 92/09690 published Jun. 11, 1992. Among them, hGH
35 or agonist variant thereof, which is produced by the

transformed *E. coli*, is particularly preferable. Such hGH or agonist variant thereof may be obtained in large quantities with high purity and homogeneity. For example, the above hGH or agonist variant thereof may be prepared according to a method disclosed in US 4,342,832, 4,601,980; US 4,898,830; US 5,424,199; and US 5,795,745. The term "substantially has the following amino acid sequence" means that the above amino acid sequence may include one or more amino-acid changes (deletion, addition, insertion or replacement) as long as such changes will not cause any disadvantageous non-similarity in function to hGH or agonist variant thereof. It is more preferable to use the hGH or agonist variant thereof substantially having an amino acid sequence, in which at least one lysine, aspartic acid, glutamic acid, unpaired cysteine residue, a free N-terminal α -amino group or a free C-terminal carboxyl group, is included.

According to the present invention, poly(ethylene glycol) is covalently bound through amino acid residues of hGH or agonist variant thereof. A variety of activated poly(ethylene glycol)s having a number of different functional groups, linkers, configurations, and molecular weights are known to one skilled in the art, which may be used to create PEG-hGH conjugates or PEG-hGH agonist variant conjugates (for reviews see Roberts M.J. et al., *Adv. Drug Del. Rev.* 54:459-476, 2002), Harris J.M. et al., *Drug Delivery Systems* 40:538-551, 2001) The amino acid residue may be any reactive one(s) having, for example, free amino, carboxyl, sulfhydryl (thiol), hydroxyl, guanidiny, or imidizoyl groups, to which a terminal reactive group of an activated poly(ethylene glycol) may be bound. The amino acid residues having the free amino groups may include lysine residues and/or N-terminal amino

acid residue, those having a free carboxyl group may include aspartic acid, glutamic acid and/or C-terminal amino acid residues, those having a free sulfhydryl (thiol) such as cysteine, those having a free hydroxyl
5 such as serine or tyrosine, those having a free guanidiny1 such as arginine, and those having a free imidizoy1 such as histidine.

In another embodiment, oxime chemistries (Lemieux & Bertozzi *Tib Tech* 16:506-513, 1998) are used to
10 target N-terminal serine residues.

The poly(ethylene glycol) used in the present invention is not restricted to any particular form or molecular weight range. The poly(ethylene glycol) molecular weight may between 500 and 100,000.
15 Normally, a molecular weight of 500-60,000 is used and preferably of from 1,000-40,000. More preferable, the molecular weight is greater than 5,000 to about 40,000.

In another embodiment the poly(ethylene glycol)
20 is a branched PEG having more than one PEG moiety attached. Preferred examples of branched PEGs are described in U.S. 5,932,462; U.S. 5,342,940; U.S. 5,643,575; U.S. 5,919,455; U.S. 6,113,906; U.S. 5,183,660; WO 02/09766; Koder Y., *Bioconjugate Chemistry* 5:283-288 (1994); and Yamasaki et al.,
25 *Agric. Biol. Chem.*, 52:2125-2127, 1998. In a preferred embodiment the molecular weight of each poly(ethylene glycol) of the branched PEG is 5,000-20,000.

Poly(alkylene oxide)s, notably poly(ethylene
30 glycol)s, are bound to hGH or agonist variant thereof via a terminal reactive group, which may or may not leave a linking moiety (spacer) between the PEG and the protein. In order to form the hGH conjugates or agonist variant thereof of the present invention,
35 polymers such as poly(alkylene oxide) are converted

into activated forms, as such term is known to those of ordinary skill in the art. The reactive group, for example, is a terminal reactive group, which mediates a bond between chemical moieties on the protein, such as amino, carboxyl or thiol groups, and poly(ethylene glycol). Typically, one or both of the terminal polymer hydroxyl end-groups, (i.e. the alpha and omega terminal hydroxyl groups) are converted into reactive functional groups, which allows covalent conjugation. This process is frequently referred to as "activation" and the poly(ethylene glycol) product having the reactive group is hereinafter referred to as "an activated poly(ethylene glycol)". Polymers containing both α and ϵ linking groups are referred to as "bis-activated poly(alkylene oxides)" and are referred to as "bifunctional". Polymers containing the same reactive group on α and ϵ terminal hydroxyls are sometimes referred to as "homobifunctional" or "homobis-activated". Polymers containing different reactive groups on α and ϵ terminal hydroxyls are sometimes referred to as "heterobifunctional" (see for example WO 01/26692) or "heterobis-activated". Polymers containing a single reactive group are referred to as "mono-activated" polyalkylene oxides or "mono-functional". Other substantially non-antigenic polymers are similarly "activated" or "functionalized".

The activated polymers are thus suitable for mediating a bond between chemical moieties on the protein, such as α - or ϵ -amino, carboxyl or thiol groups, and poly(ethylene glycol). Bis-activated polymers can react in this manner with two protein molecules or one protein molecule and a reactive small molecule in another embodiment to effectively form

protein polymers or protein-small molecule conjugates through cross linkages.

Functional groups capable of reacting with either the amino terminal α -amino group or ϵ -amino groups of lysines found on the hGH or agonist variant thereof include: N-hydroxysuccinimidyl esters, carbonates such as the p-nitrophenyl, or succinimidyl (US 5,808,096, 5,612,460, US 5,324,844, US 5,512,614); carbonyl imidazole; azlactones (US 5,321,095, US 5,567,422); cyclic imide thiones (US 5,405,877, 5,349,001); isocyanates or isothiocyanates (Greenwald R.B., *J. Org. Chem.*, 60:331-336, 1995); tresyl chloride (EP 714 402, EP 439 508); halogen formiates (WO 96/40792), and aldehydes.

Functional groups capable of reacting with carboxylic acid groups, reactive carbonyl groups and oxidized carbohydrate moieties on hGH or agonist variant thereof include; primary amines; and hydrazine and hydrazide functional groups such as the acyl hydrazides, carbazates, semicarbamates, thiocarbazates, etc (WO 01/70685).

Mercapto groups, if available on the hGH or agonist variant thereof, can also be used as attachment sites for suitably activated polymers with reactive groups such as thiols; maleimides, sulfones, and phenyl glyoxals; see, for example, U.S. Pat. No. 5,093,531, the disclosure of which is hereby incorporated by reference. Other nucleophiles capable of reacting with an electrophilic center include, but are not limited to, for example, hydroxyl, amino, carboxyl, thiol, active methylene and the like.

Also included are polymers including lipophilic and hydrophilic moieties disclosed in US 5,359,030 and US 5,681,811; US 5,438,040; and US 5,359,030.

As well halogenated PEGs are disclosed on WO 98/32466 that can react with amino, thiol groups, and aromatic hydroxy groups, which directly covalently attach the PEG to the protein.

- 5 In one preferred embodiment of the invention secondary amine or amide linkages are formed using the N-terminal α -amino group or ϵ -amino groups of lysine of hGH or agonist variant thereof and the activated PEG. In another preferred aspect of the invention, a
- 10 secondary amine linkage is formed between the N-terminal primary α - or ϵ -amino group of hGH or agonist variant thereof and single or branched chain PEG aldehyde by reduction with a suitable reducing agent such as NaCNBH₃, NaBH₃, Pyridine Borane etc. as
- 15 described in Chamow et al., *Bioconjugate Chem.* 5: 133-140 (1994) and US Pat. No 5,824,784.

- In a preferred embodiment at least 70%, preferably at least 80%, preferably at least 81%, preferably at least 82%, preferably at least 83%,
- 20 preferably at least 84%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91%, preferably at least 92%, preferably at least 93%,
- 25 preferably at least 94%, preferably at least 95%, preferably at least 96%, preferably at least 97%, and most preferably at least 98% of the poly(ethylene glycol) is on the amino terminal α -amino group.

- In another preferred embodiment of the invention,
- 30 polymers activated with amide-forming linkers such as succinimidyl esters, cyclic imide thiones, or the like are used to effect the linkage between the hGH or agonist variant thereof and polymer, see for example, U.S. Pat. No. 5,349,001; U.S. Pat. No. 5,405,877; and
- 35 Greenwald, et al., *Crit. Rev. Ther. Drug Carrier Syst.*

17:101-161, 2000, which are incorporated herein by reference. One preferred activated poly(ethylene glycol), which may be bound to the free amino groups of hGH or agonist variant thereof includes single or
5 branched chain N-hydroxysuccinylimide poly(ethylene glycol) may be prepared by activating succinic acid esters of poly(ethylene glycol) with N-hydroxysuccinylimide.

Other preferred embodiments of the invention
10 include using other activated polymers to form covalent linkages of the polymer with the hGH or agonist variant thereof via ϵ -amino or other groups. For example, isocyanate or isothiocyanate forms of terminally activated polymers can be used to form urea
15 or thiourea-based linkages with the lysine amino groups (Greenwald R.B., *J. Org. Chem.*, 60:331-336, 1995).

In another preferred aspect of the invention, carbamate (urethane) linkages are formed with protein
20 amino groups as described in U.S. Pat. Nos. 5,122,614, 5,324,844, and 5,612,640, which are hereby incorporated by reference. Examples include N-succinimidyl carbonate, para-nitrophenyl carbonate, and carbonyl imidazole activated polymers. In another
25 preferred embodiment of this invention, a benzotriazole carbonate derivative of PEG is linked to amino groups on hGH or agonist variant thereof.

Another aspect of the invention represents a prodrug or sustained release form of hGH or agonist
30 variant thereof, comprised of a water soluble polymer, such as poly(ethylene glycol), attached to an hGH or agonist variant thereof molecule by a functional linker that can predictably break down by enzymatic or pH directed hydrolysis to release free hGH or agonist
35 variant thereof or other hGH or agonist variant

thereof derivative. The prodrug can also be a "double prodrug" (Bundgaard in *Advanced Drug Delivery Reviews* 3:39-65, 1989) involving the use of a cascade latentiation. In such systems, the hydrolytic reaction involves an initial rate-limiting (slow) enzymatic or pH directed step and a second step involving a rapid non-enzymatic hydrolysis that occurs only after the first has taken place. Such a releasable polymer provides protein conjugates, which are impermanent and could act as a reservoir, that continually discharge hGH or agonist variant thereof. Such functional linkers are described in US 5,614,549; US 5,840,900; US 5,880,131; US 5,965,119; us 5,965,565; US 6,011,042; US 6,153,655; US 6,180,095 B1; US 6,413,507; Greenwald R.B. et al., *J. Med. Chem.* 42:3657-3667, 1999; Lee, S. et al., *Bioconjugate Chem* 12:163-169, 2001; Garman A.J. et al., *FEBS Lett.* 223:361-365, 1987; Woghiren C. et al., *Bioconjugate Chem.* 4:314-318, 1993; Roberts M.J. et al., *J. Pharm. Sci.* 87:1440-1445, 1998; Zhao X., in *Ninth Int. Symp. Recent Adv. Drug Delivery Syst.* 199; Greenwald R.B. et al., *J. Med. Chem.* 43:475-487, 2000; and Greenwald R.B. *Crit. Rev. Ther. Drug Carrier Syst.* 17:101-161, 2000. Zalipsky et al., 28th Int. Symp. On controlled Release of Bioactive Materials 1; 73-74,2001

Conjugation reactions, referred to as pegylation reactions, were historically carried out in solution with molar excess of polymer and without regard to where the polymer will attach to the protein. Such general techniques, however, have typically been proven inadequate for conjugating bioactive proteins to non-antigenic polymers while retaining sufficient bioactivity. One way to maintain the hGH or agonist

variant thereof bioactivity is to substantially avoid the conjugation of those hGH or agonist variant thereof reactive groups associated with the receptor binding site(s) in the polymer coupling process.

- 5 Another aspect of the present invention is to provide a process of conjugating poly(ethylene glycol) to hGH or agonist variant thereof maintaining high levels of retained activity.

- The chemical modification through a covalent
10 bond may be performed under any suitable condition generally adopted in a reaction of a biologically active substance with the activated poly(ethylene glycol). The conjugation reaction is carried out under relatively mild conditions to avoid inactivating the
15 hGH or agonist variant thereof. Mild conditions include maintaining the pH of the reaction solution in the range of 3 to 10 and the reaction temperatures within the range of from about 0°-37°C. In the cases where the reactive amino acid residues in hGH or
20 agonist variant thereof have free amino groups, the above modification is preferably carried out in a non-limiting list of suitable buffers (pH 3 to 10), including phosphate, MES, citrate, acetate, succinate or HEPES, for 1-48 hrs at 4°-37°C. In targeting N-
25 terminal amino groups with reagents such as PEG aldehydes pH 4-8 is preferably maintained. The activated poly(ethylene glycol) may be used in about 0.05-100 times, preferably about 0.01 -2.5 times, the molar amount of the number of free amino groups of hGH
30 or agonist variant thereof. On the other hand, where reactive amino acid residues in hGH or agonist variant thereof have the free carboxyl groups, the above modification is preferably carried out in pH from about 3.5 to about 5.5, for example, the modification
35 with poly(oxyethylenediamine) is carried out in the

presence of carbodiimide (pH 3.5-5) for 1-24 hrs at 4°
-37°C. The activated poly(ethylene glycol) may be used
in 0.05-300 times the molar amount of the number of
free carboxyl groups of hGH or agonist variant
5 thereof.

In separate embodiments, the upper limit for the
amount of polymer included in the conjugation
reactions exceeds about 1:1 to the extent that it is
possible to react the activated polymer and hGH or
10 agonist variant thereof without forming a substantial
amount of high molecular weight species, i.e. more
than about 20% of the conjugates containing more than
about one strand of polymer per molecule of hGH or
agonist variant thereof. For example, it is
15 contemplated in this aspect of the invention that
ratios of up to about 6:1 can be employed to form
significant amounts of the desired conjugates which
can thereafter be isolated from any high molecular
weight species.

20 In another aspect of this invention,
bifunctionally activated PEG derivatives may be used
to generate polymeric hGH or agonist variant thereof-
PEG molecules in which multiple hGH or agonist variant
thereof molecules are crosslinked via PEG. Although
25 the reaction conditions described herein can result in
significant amounts of unmodified hGH or agonist
variant thereof, the unmodified hGH or agonist variant
thereof can be readily recycled into future batches
for additional conjugation reactions. The processes of
30 the present invention generate surprisingly very
little, i.e. less than about 30% and more preferably,
less than about 10%, of high molecular weight species
and species containing more than one polymer strand
per hGH or agonist variant thereof. These reaction
35 conditions are to be contrasted with those typically

used for polymeric conjugation reactions wherein the activated polymer is present in several-fold molar excesses with respect to the target. In other aspects of the invention, the polymer is present in amounts of
5 from about 0.1/amino group to about 50 equivalents per equivalent of hGH or agonist variant thereof. In other aspects of the invention, the polymer is present in amounts of from about 1 to about 10 equivalents per equivalent of hGH or agonist variant thereof.

10 The conjugation reactions of the present invention initially provide a reaction mixture or pool containing mono- and di-PEG-hGH conjugates, unreacted hGH, unreacted polymer, and usually less than about 20% high molecular weight species. The high molecular
15 weight species include conjugates containing more than one polymer strand and/or polymerized PEG-hGH or agonist variant thereof species. After the unreacted species and high molecular weight species have been removed, compositions containing primarily mono- and
20 di-polymer-hGH or agonist variant thereof conjugates are recovered. Given the fact that the conjugates for the most part include a single polymer strand, the conjugates are substantially homogeneous. These modified hGH or agonist variant thereof have at least
25 about 0.1% of the *in vitro* biological activity associated with the native or unmodified hGH or agonist variant thereof as measured using standard FDC-P1 cell proliferation assays, (Clark et al. *Journal of Biological Chemistry* 271:21969-21977,
30 1996), receptor binding assay (US 5,057,417), or hypophysectomized rat growth (Clark et al. *Journal of Biological Chemistry* 271:21969-21977, 1996). In preferred aspects of the invention, however, the modified hGH or agonist variant thereof have about 25%
35 of the *in vitro* biological activity, more preferably,

the modified hGH or agonist variant thereof have about 50% of the *in vitro* biological activity, more preferably, the modified hGH or agonist variant thereof have about 75% of the *in vitro* biological activity, and most preferably the modified hGH or agonist variant thereof have equivalent or improved *in vitro* biological activity.

The processes of the present invention preferably include rather limited ratios of polymer to hGH or agonist variant thereof. Thus, the hGH or agonist variant thereof conjugates have been found to be predominantly limited to species containing only one strand of polymer. Furthermore, the attachment of the polymer to the hGH or agonist variant thereof reactive groups is substantially less random than when higher molar excesses of polymer linker are used. The unmodified hGH or agonist variant thereof present in the reaction pool, after the conjugation reaction has been quenched, can be recycled into future reactions using ion exchange or size exclusion chromatography or similar separation techniques.

A poly(ethylene glycol)-modified hGH or agonist variant thereof, namely chemically modified protein according to the present invention, may be purified from a reaction mixture by conventional methods which are used for purification of proteins, such as dialysis, salting-out, ultrafiltration, ion-exchange chromatography, hydrophobic interaction chromatography (HIC), gel chromatography and electrophoresis. Ion-exchange chromatography is particularly effective in removing unreacted poly(ethylene glycol) and hGH or agonist variant thereof. In a further embodiment of the invention, the mono- and di-polymer-hGH or agonist variant thereof species are isolated from the reaction mixture to remove high molecular weight species, and

unmodified hGH or agonist variant thereof. Separation is effected by placing the mixed species in a buffer solution containing from about 0.5-10 mg/mL of the hGH or agonist variant thereof-polymer conjugates.

- 5 Suitable solutions have a pH from about 4 to about 8. The solutions preferably contain one or more buffer salts selected from KCl, NaCl, K_2HPO_4 , KH_2PO_4 , Na_2HPO_4 , NaH_2PO_4 , $NaHCO_3$, $NaBO_4$, CH_3CO_2H , and NaOH.

- Depending upon the reaction buffer, the hGH or
10 agonist variant thereof polymer conjugate solution may first have to undergo buffer exchange/ultrafiltration to remove any unreacted polymer. For example, the PEG-hGH or agonist variant thereof conjugate solution can be ultrafiltered across a low molecular weight cut-off
15 (10,000 to 30,000 Dalton) membrane to remove most unwanted materials such as unreacted polymer, surfactants, if present, or the like.

- The fractionation of the conjugates into a pool containing the desired species is preferably carried
20 out using an ion exchange chromatography medium. Such media are capable of selectively binding PEG-hGH or agonist variant thereof conjugates via differences in charge, which vary in a somewhat predictable fashion. For example, the surface charge of hGH or agonist
25 variant thereof is determined by the number of available charged groups on the surface of the protein. These charged groups typically serve as the point of potential attachment of poly(alkylene oxide) polymers. Therefore, hGH or agonist variant thereof
30 conjugates will have a different charge from the other species to allow selective isolation.

- Strongly polar anion or cation exchange resins such as quaternary amine or sulfopropyl resins, respectively, are used for the method of the present
35 invention. Ion exchange resins are especially

preferred. A non-limiting list of included commercially available cation exchange resins suitable for use with the present invention are SP-hitrap®, SP Sepharose HP® and SP Sepharose® fast flow. Other
5 suitable cation exchange resins e.g. S and CM resins can also be used. A non-limiting list of anion exchange resins, including commercially available anion exchange resins, suitable for use with the present invention are Q-hitrap®, Q Sepharose HP®, and
10 Q sepharose® fast flow. Other suitable anion exchange resins, e.g. DEAE resins, can also be used.

For example, the anion or cation exchange resin is preferably packed in a column and equilibrated by conventional means. A buffer having the same pH and
15 osmolality as the polymer conjugated hGH or agonist variant thereof solution is used. The elution buffer preferably contains one or more salts selected from KCl, NaCl, K_2HPO_4 , KH_2PO_4 , Na_2HPO_4 , NaH_2PO_4 , $NaHCO_3$, $NaBO_4$, and $(NH_4)_2CO_3$. The conjugate-containing solution
20 is then adsorbed onto the column with unreacted polymer and some high molecular weight species not being retained. At the completion of the loading, a gradient flow of an elution buffer with increasing salt concentrations is applied to the column to elute
25 the desired fraction of polyalkylene oxide-conjugated hGH or agonist variant thereof. The eluted pooled fractions are preferably limited to uniform polymer conjugates after the cation or anion exchange separation step. Any unconjugated hGH or agonist
30 variant thereof species can then be back washed from the column by conventional techniques. If desired, mono and multiply pegylated hGH or agonist variant thereof species can be further separated from each

other via additional ion exchange chromatography or size exclusion chromatography.

Techniques utilizing multiple isocratic steps of increasing concentration of salt or pH can also be
5 used. Multiple isocratic elution steps of increasing concentration will result in the sequential elution of di- and then mono-hGH or agonist variant thereof-polymer conjugates.

The temperature range for elution is between
10 about 4°C and about 25°C. Preferably, elution is carried out at a temperature of from about 4°C to about 22°C. For example, the elution of the PEG-hGH or agonist variant thereof fraction is detected by UV absorbance at 280 nm. Fraction collection may be
15 achieved through simple time elution profiles.

A surfactant can be used in the processes of conjugating the poly(ethylene glycol) polymer with the hGH or agonist variant thereof moiety. Suitable surfactants include ionic-type agents such as sodium
20 dodecyl sulfate (SDS). Other ionic surfactants such as lithium dodecyl sulfate, quaternary ammonium compounds, taurocholic acid, caprylic acid, decane sulfonic acid, etc. can also be used. Non-ionic surfactants can also be used. For example, materials
25 such as poly(oxyethylene) sorbitans (Tweens), poly(oxyethylene) ethers (Tritons) can be used. See also Neugebauer, A Guide to the Properties and Uses of Detergents in Biology and Biochemistry (1992) Calbiochem Corp. The only limitations on the
30 surfactants used in the processes of the invention are that they are used under conditions and at concentrations that do not cause substantial irreversible denaturation of the hGH or agonist variant thereof and do not completely inhibit polymer
35 conjugation. The surfactants are present in the

reaction mixtures in amounts from about 0.01-0.5%; preferably from 0.05-0.5%; and most preferably from about 0.075-0.25%. Mixtures of the surfactants are also contemplated.

5 It is thought that the surfactants provide a temporary, reversible protecting system during the polymer conjugation process. Surfactants have been shown to be effective in selectively discouraging polymer aggregates while allowing lysine-based or
10 amino terminal-based conjugation to proceed.

 The present poly(ethylene glycol)-modified hGH or agonist variant thereof has a more enduring pharmacological effect, which may be possibly attributed to its prolonged half-life *in vivo*.

15 Furthermore, the present poly(ethylene glycol)-modified hGH or agonist variant thereof may be useful for the treatment of hypo pituitary dwarfism (GHD), Adult Growth Hormone Deficiency, Turner's syndrome, growth failure in children who were born short for
20 gestational age (SGA), Prader-Willi syndrome (PWS), chronic renal insufficiency (CRI), Aids wasting, and Aging.

 The present poly(ethylene glycol)-modified hGH or agonist variant thereof may be formulated into
25 pharmaceuticals containing also a pharmaceutically acceptable diluent, an agent for preparing an isotonic solution, a pH-conditioner and the like in order to administer them into a patient.

 The above pharmaceuticals may be administered
30 subcutaneously, intramuscularly, intravenously, pulmonary, intradermally, or orally, depending on a purpose of treatment. A dose may be also based on the kind and condition of the disorder of a patient to be treated, being normally between 0.1 mg and 5 mg by

injection and between 0.1 mg and 50 mg in an oral administration for an adult

The polymeric substances included are also preferably water-soluble at room temperature. A non-limiting list of such polymers include poly(alkylene oxide) homopolymers such as poly(ethylene glycol) or poly(propylene glycols), poly(oxyethylenated polyols), copolymers thereof and block copolymers thereof, provided that the water solubility of the block copolymers is maintained.

As an alternative to PEG-based polymers, effectively non-antigenic materials such as dextran, poly(vinyl pyrrolidones), poly(acrylamides), poly(vinyl alcohols), carbohydrate-based polymers, and the like can be used. Indeed, the activation of α - and ω -terminal groups of these polymeric substances can be effected in fashions similar to that used to convert poly(alkylene oxides) and thus will be apparent to those of ordinary skill. Those of ordinary skill in the art will realize that the foregoing list is merely illustrative and that all polymer materials having the qualities described herein are contemplated. For purposes of the present invention, "effectively non-antigenic" means all materials understood in the art as being nontoxic and not eliciting an appreciable immunogenic response in mammals.

Definitions

The following is a list of abbreviations and the corresponding meanings as used interchangeably herein:

g	gram(s)
mg	milligram(s)
ml or mL	milliliter(s)

RT room temperature
PEG poly (ethylene glycol)

5 The complete content of all publications, patents, and patent applications cited in this disclosure are herein incorporated by reference as if each individual publication, patent, or patent application were specifically and individually indicated to be incorporated by reference.

10 Although the foregoing invention has been described in some detail by way of illustration and example for the purposes of clarity of understanding, it will be readily apparent to one skilled in the art in light of the teachings of this invention that
15 changes and modifications can be made without departing from the spirit and scope of the present invention. The following examples are provided for exemplification purposes only and are not intended to limit the scope of the invention, which has been
20 described in broad terms above.


 In the following examples, the hGH is that of SEQ ID NO:1. It is understood that other members of the hGH or agonist variant thereof family of polypeptides could also be pegylated in a similar manner as
25 exemplified in the subsequent examples.

 All references, patents or applications cited herein are incorporated by reference in their entirety as if written herein.
30

 The present invention will be further illustrated by referring to the following examples, which however, are not to be construed as limiting the scope of the present invention.
35

EXAMPLE 1

Straight Chain 20,000 MW PEG-ALD hGH



This example demonstrates a method for generation of substantially homogeneous preparations of N-terminally monopegylated hGH by reductive alkylation. Methoxy-
 10 linear PEG-propionaldehyde reagent of approximately 20,000 MW (Shearwater Corp.) was selectively coupled via reductive amination to the N-terminus of hGH by taking advantage of the difference in the relative pK_a value of the primary amine at the N-terminus versus
 15 pK_a values of primary amines at the ε-amino position of lysine residues. hGH protein dissolved at 10 mg/mL in 25 mM MES (Sigma Chemical, St. Louis, MO) pH 6.0, 25 mM Hepes (Sigma Chemical, St. Louis, MO) pH 7.0, or in 10 mM Sodium Acetate (Sigma Chemical, St. Louis,
 20 MO) pH 4.5, was reacted with Methoxy-PEG-propionaldehyde, M-PEG-ALD, (Shearwater Corp., Huntsville, AL) by addition of M-PEG-ALD to yield a relative PEG:hGH molar ratio of 0.1:0.7 per amine (optionally 8% acetonitrile may also be added).
 25 Reactions were catalyzed by addition of stock 1M NaCNBH₄ (Sigma Chemical, St. Louis, MO), dissolved in H₂O, to a final concentration of 10-50 mM. Reactions were carried out in the dark at 4°C to RT for 18-24 hours. Reactions were stopped by addition of 1 M Tris
 30 (Sigma Chemical, St. Louis, MO) ~pH 7.6 to a final Tris concentration of 50 mM or diluted into appropriate buffer for immediate purification.

EXAMPLE 2

Straight Chain 30,000 MW PEG-ALD hGH

Methoxy-linear 30,000 MW PEG-propionaldehyde reagent
 5 (Shearwater Corp.) was coupled to the N-terminus of
 hGH using the procedure described for Example 1.

EXAMPLE 3


10 Straight chain 5,000 MW PEG-ALD hGH

Methoxy-linear 5,000 MW PEG-propionaldehyde reagent
 (Fluka) was coupled to the N-terminus of hGH using the
 procedure described for Example 1.

15

EXAMPLE 4

Branched chain 40,000 MW PEG-ALD hGH



20

Methoxy-branched 40,000 MW PEG-aldehyde (PEG2-ALD)
 reagent (Shearwater Corp.) was coupled to the N-
 terminus of hGH using the procedure described for
 25 Example 1.


EXAMPLE 5

Branched chain 20,000 MW PEG-ALD hGH

Methoxy-branched 20,000 MW PEG-aldehyde (PEG2-ALD) reagent (Shearwater Corp.) was coupled to the N-terminus of hGH using the procedure described for
5 Example 1 using PEG to hGH molar ratios of 0.1-0.5 per amine.

EXAMPLE 6

10 Straight chain 30,000 MW SPA-PEG hGH



This example demonstrates a method for generation of
15 substantially homogeneous preparations of mono-pegylated hGH using N-hydroxysuccinimidyl (NHS) active esters. hGH protein stock solution was dissolved at 10 mg/mL in 0.25 M HEPES buffer, pH 7.2 (optionally 8% acetonitrile may also be added). The solution was
20 then reacted with Methoxy-PEG-succinimidyl propionate (SPA-PEG) by addition of SPA-PEG to yield a relative PEG:hGH molar ratio of 0.1-0.65 per amine. Reactions were carried out at 4°C to RT for from 5 minutes to 1 hour. Reactions were stopped by lowering the pH to 4.0
25 with 0.1 N acetic acid or by adding a 5X molar excess of Tris HCl.

EXAMPLE 7


30 Straight chain 20,000 MW SPA-PEG hGH

Straight chain 20,000 MW SPA-PEG reagent (Shearwater Corp.) was coupled to the N-terminus of hGH using the procedure described for Example 6

5

EXAMPLE 8

Straight chain 3,400 MW Biotin-SPA-PEG-hGH




10

3,400 MW Biotin-PEG-CO₂-NHS reagent (Shearwater Corp.) is coupled to hGH using the procedure described for Example 6.

15

EXAMPLE 9

Branched 10,000 MW NHS-PEG-hGH



10,000 MW branched PEG2-NHS (Shearwater Corp.) is
coupled to hGH using the procedure described for
5 Example 6.

EXAMPLE 10


Branched 20,000 MW NHS-PEG-hGH
10 20,000 MW branched PEG2-NHS (Shearwater Corp.) is
coupled to hGH using the procedure described for
Example 6.

15 EXAMPLE 111

Branched 40,000 MW NHS-PEG-hGH
40,000 MW branched PEG2-NHS (Shearwater Corp.) was
20 coupled to hGH using the procedure described for
Example 6.

EXAMPLE 12

25 Straight chain 20,000 MW PEG-BTC-hGH




20,000 MW PEG-BTC (Shearwater Corp.) is coupled to hGH using the procedure described for Example 6. This example demonstrates a method for generation of substantially homogeneous preparations of pegylated hGH using benzotriazole carbonate derivatives of PEG.

EXAMPLE 13

10

Straight chain 5,000 MW PEG-SS-hGH




15 5,000 MW succinimidyl succinate-PEG (SS-PEG) (Shearwater Corp.) is coupled to hGH using the procedure described for Example 6. This example demonstrates a method for generation of substantially homogeneous preparations of pegylated hGH using a hydrolyzable linkage.

20

EXAMPLE 14

Straight chain 20,000 MW PEG-CM-HBA-hGH

25



20,000 MW carboxymethyl hydroxybutyric acid-PEG (CM-HBA-PEG) (Shearwater Corp.) was coupled to hGH using
 5 the procedure described for Example 6. This example demonstrates a method for generation of substantially homogeneous preparations of pegylated hGH using a hydrolyzable linkage.

10 EXAMPLE 15


Straight chain 2-4x 5,000 MW PEG-CM-HBA-hGH

5,000 MW PEG-CM-HBA (Shearwater Corp.) was coupled to
 15 hGH using the procedure described for Example 13.

EXAMPLE 16

Straight chain 20,000 MW HZ-PEG hGH

20



This example demonstrates a method for generation of substantially homogeneous preparations of pegylated
 25 hGH using 20,000 MW methoxy-PEG-hydrazide, HZ-PEG (Shearwater Corp.). hGH protein stock solution was dissolved at 10 mg/mL in 10 mM MES, pH 4.0. The solution was then reacted with HZ-PEG by addition of solid to yield a relative PEG:hGH molar ratio of 0.1-
 30 5.0 per carboxyl group. Reactions were catalyzed with carbodiimide (EDC, EOAC, EDEC) at a final concentration of 2 mM to 4 mM. Reactions were carried

out at 4°C for 2 hours to overnight or room temperature from 10 minutes to overnight. Reactions were stopped by Removing the unconjugated PEG and the carbodiimide by purification on cation exchange.

5

EXAMPLES 17

Multi-pegylated species

- 10 Modified hGHs having two or more PEGs (multi-pegylated) attached were also obtained from Examples 1 and 4 and were separated from the mono-pegylated species using anion exchange chromatography. Modified hGHs having two or more PEGs (multi-pegylated)
- 15 attached are also separated from mono-PEGylated species using cation exchange chromatography. Modified hGHs having two or more PEGs (multi-pegylated) attached are also obtained in examples 2,3,5-13 and are purified in similar fashion to
- 20 examples 1 and 4.

EXAMPLE 18

Purification of Pegylated hGH

25

Pegylated hGH species were purified from the reaction mixture to >95% (SEC analysis) using a single ion exchange chromatography step

30 *Anion exchange chromatography*

The PEG hGH species were purified from the reaction mixture to >95% (SEC analysis) using a single anion exchange chromatography step. Mono-pegylated hGH was purified from unmodified hGH and multi-pegylated hGH

35 species using anion exchange chromatography. A

typical 20K aldehyde hGH reaction mixture (5-100 mg protein), as described above, was purified on a Q-Sepharose Hitrap column (1 or 5 mL) (Amersham Pharmacia Biotech, Piscataway, NJ) or Q-Sepharose fast flow column (26/20, 70 mL bed volume) (Amersham Pharmacia Biotech, Piscataway, NJ) equilibrated in 25 mM HEPES, pH 7.3 (Buffer A). The reaction mixture was diluted 5-10X with buffer A and loaded onto the column at a flow rate of 2.5 mL/min. The column was washed with 8 column volumes of buffer A. Subsequently, the various hGH species were eluted from the column in 80-100 column volumes of Buffer A and a linear NaCl gradient of 0-100 mM. The eluant was monitored by absorbance at 280 nm (A_{280}) and 5 mL fractions were collected. Fractions were pooled as to extent of pegylation, e.g., mono, di, tri etc. (as assessed in example 15). The pool was then concentrated to 0.5-5 mg/mL in a Centriprep YM10 concentrator (Amicon, Technology Corporation, Northborough, MA). Protein concentration of pool was determined by A_{280} using an extinction coefficient of 0.78. Total yield of purified mono 20 K PEG-aldehyde hGH from this process was 25-30 %.

Cation Exchange Chromatography

Cation exchange chromatography is carried out on an SP Sepharose high performance column (Pharmacia XK 26/20, 70 ml bed volume) equilibrated in 10 mM sodium acetate pH 4.0 (Buffer B). The reaction mixture is diluted 10X with buffer B and loaded onto the column at a flow rate of 5 mL/min. Next the column is washed with 5 column volumes of buffer B, followed by 5 column volumes of 12% buffer C (10 mM acetate pH 4.5, 1 M NaCl). Subsequently, the PEG-hGH species is eluted from the column with a linear gradient of 12 to 27% buffer C in 20 column volumes. The eluant is

monitored at 280 nm and 10 mL fractions are collected. Fractions are pooled according to extent of pegylation (mono, di, tri etc.), exchanged into 10 mM acetate pH 4.5 buffer and concentrated to 1-5 mg/mL in a stirred
5 cell fitted with an Amicon YM10 membrane. Protein concentration of pool is determined by A280 nm using an extinction coefficient of 0.78. Total yield of monopegylated hGH from this process is 10 to 50%.

10

EXAMPLE 19

Biochemical Characterization

The purified pegylated hGH pools were characterized by
15 reducing and non-reducing SDS-PAGE, non-denaturing and denaturing Size Exclusion Chromatography, analytical Anion Exchange Chromatography, N-terminal Sequencing, Hydrophobic Interaction Chromatography, and Reversed Phase HPLC.

20

*Size Exclusion High Performance Liquid Chromatography (SEC-HPLC)**Non-denaturing SEC-HPLC*

25 The reaction of Methoxy-PEG of various attachment chemistries, sizes, linkers, and geometries with hGH, anion exchange purification pools and final purified products were assessed using non-denaturing SEC-HPLC. Analytical non-denaturing SEC-HPLC was carried out
30 using a Tosohaas G4000PWXL column, 7.8 mm X 30 cm, (Tosohaas Amersham Bioscience, Piscataway, NJ) or Superdex 200 (Amersham Bioscience, Piscataway, NJ) in 20 mM Phosphate pH 7.2, 150 mM NaCl at a flow rate of 0.5 mL/minute. PEGylation greatly increases the
35 hydrodynamic volume of the protein resulting in a

shift to an earlier retention time. New species were observed in the PEG aldehyde hGH reaction mixtures along with unmodified hGH. These PEGylated and non-PEGylated species were separated on Q-Sepharose chromatography, and the resultant purified mono PEG-Aldehyde hGH species were subsequently shown to elute as a single peak on non-denaturing SEC (> 95% purity). The Q-Sepharose chromatography step effectively removed free PEG, hGH, and multi PEGylated hGH species from the mono-Pegylated hGH. Non-denaturing SEC-HPLC demonstrated that the effective size of the various PEGylated-hGH was much greater than their respective theoretical molecular weights (Table 1)

Table 1
Size Exclusion Chromatography (SEC)

	MW (Theoretical)	Size (SEC)
hGH	22,000	21,000
4-6x5K PEG-SPA GH	47,000	128,000
2-4x5K PEG-CMHBA (NHS) GH	37,000	71,000
20K PEG-ALD GH	42,000	120,000
20K Branched PEG-ALD GH	42,000	114,000
20K PEG-CMHBA (NHS) GH	42,000	115,000
20k PEG-Hydrazide GH	42,000	125,000
2x20K PEG-ALD GH	62,000	250,000
30K PEG-ALD GH	52,000	231,000
30K PEG-SPA GH	52,000	183,000
2x30K PEG-SPA GH	82,000	569,000
40K Branched PEG-ALD GH	62,000	330,000
40K Branched PEG-NHS GH	62,000	253,000

Denaturing SEC-HPLC

The reaction of the various Methoxy-PEGs with hGH, anion exchange purification, and final purified products were assessed using denaturing SEC-HPLC.

- 5 Analytical denaturing SEC-HPLC was carried out using a Tosohaas 3000SWXL column 7.8 mm X 30cm (Tosohaas Pharmacia Biotech, Piscataway, NJ) in 100 mM Phosphate pH 6.8, 0.1% SDS at a flow rate of 0.8 mL/minute. PEGylation greatly increases the hydrodynamic volume
- 10 of the protein resulting in a shift to an earlier retention time. New species were observed in the 20K PEG aldehyde hGH reaction mixture along with unmodified hGH. These PEGylated and non-PEGylated species were separated on Q-Sepharose chromatography,
- 15 and the resultant purified mono 20K PEG-Aldehyde hGH was subsequently shown to elute as a single peak on denaturing SEC(> 95% purity). The Q-Sepharose chromatography step effectively removed free PEG, hGH, and multi PEGylated hGH species from the mono-
- 20 Pegylated hGH.

SDS PAGE/PVDF transfer

- SDS-PAGE was used to assess the reaction of the
- 25 various PEG reagents with hGH and the purified final products. Examples of this technique are shown with mono 20K linear and branched 20K and 40K PEG aldehyde, and 4X6 5K SPA PEG. (Figures 1 & 2). SDS-PAGE was carried out on 1 mm thick 10-20% Tris tricine gels
- 30 (Invitrogen, Carlsbad, CA) under reducing and non-reducing conditions and stained using a Novex Colloidal Coomassie™ G-250 staining kit (Invitrogen, Carlsbad, CA). Purified mono PEG-aldehyde hGH species migrate as one major band on SDS-PAGE. Bands were
- 35 blotted onto PVDF membrane for subsequent N-terminal

sequence identification.

Analytical anion exchange HPLC

5 Analytical anion exchange HPLC was used to assess the reaction of various mPEGs with hGH, anion exchange purification fractions and final purified products. Analytical anion exchange HPLC was carried out using a Tosohaas Q5PW or DEAE-PW anion exchange column, 7.5 mm
10 x 75 mm (Tosohaas Pharmacia Biotech, Piscataway, NJ) in 50 mM Tris pH 8.6 at a flow rate of 1 mL/min. Samples were eluted with a linear gradient of 5-200 mM NaCl.

15 *Reversed phase HPLC (RP-HPLC)*

PEG-GH reaction mixtures and purified PEGylated products were analyzed by RP HPLC to elucidate hGH species, mono and multiply PEGylated hGH species, and,
20 to monitor oxidized hGH forms, as well as, PEG hGH isoforms having a single PEG linked at different sites (e.g. N-terminus vs Lysine ϵ -amino groups). RP-HPLC was carried out utilizing a Zorbax SB-CN 150 or 250 mm x 4.6 mm (3.5 mm or 5 mm) reversed phase HPLC column.
25 Experiments were conducted at ambient temperature on a typical load of 10 mg of protein per sample. Buffer A is 0.1% trifluoroacetic acid in water; Buffer B is 0.1% trifluoroacetic acid in acetonitrile. The gradient, which results in a 1% increase in B per
30 minute, is as follows:

Step	Time	Flow	%A	%B	Step
0	0	1	60	40	0
1	3	1	60	40	0
2	20	1	50	50	1
3	2	1	60	40	1
4	6	1	60	40	0

N-terminal Sequence and Peptide Mapping

5 Automated Edman degradation chemistry was used to determine the NH₂-terminal protein sequence. An Applied Biosystems Model 494 Procise sequencer (Perkin Elmer, Wellesley, MA) was employed for the degradation. The respective PTH-AA derivatives were
10 identified by RP-HPLC analysis in an on-line fashion employing an Applied Biosystems Model 140C PTH analyzer fitted with a Perkin Elmer/Brownlee 2.1 mm i.d. PTH-C18 column. 20K linear and 20 and 40K branched PEG-ALD hGH Protein bands transferred to PVDF
15 membranes or solutions of purified 20K linear and branched 20 and 40K PEG-ALD hGH were sequenced. Purified 20K linear PEG-hGH yielded a major signal (approximately 88% yield) was observed that had the expected sequence for hGH except for the absence of
20 the N-terminal amino acid. This result is as expected for a protein N-terminally PEGylated via the aldehyde chemistry. The residue of the first cycle is unrecoverable due to the attached PEG moiety. A minor signal (approximately 12% yield) had the correct N-
25 terminal amino acid sequence. Considering that the peak collected off the RP-HPLC is 100% PEGylated, these data suggest that approximately 88% of the PEG modification is at the N-terminus with remainder apparently linked to one of several possible lysine

residues.

Tryptic digests were performed at a concentration of 1 mg/mL and, typically, 50 ug of material is used per digest. Trypsin was added such that the trypsin to PEG-hGH ratio was 1:30 (w/w). Tris buffer was present at 30 mM, pH 7.5. Samples were incubated at room temperature for 16 ± 0.5 hours. Reactions were quenched by the addition of 50 μ L of 1N HCl per mL of digestion solution. Samples were diluted, prior to placing the samples in the autosampler, to a final concentration of 0.25 mg/mL in 6.25 % acetonitrile. Acetonitrile is added first (to 19.8% acetonitrile), mixed gently, and then water is added to final volume (four times the starting volume). Extra digestion solution may be removed and stored for up to 1 week at -20°C .

A Waters Alliance 2695 HPLC system was used for analysis, but other systems should produce similar results. The column used was an Astec C-4 polymeric 25 cm x 4.6 mm column with 5 μ m particles. Experiments were conducted at ambient temperature on a typical load of 50 μ g of protein per sample. Buffer A is 0.1% trifluoroacetic acid in water; buffer B is 0.085% trifluoroacetic acid in acetonitrile. The gradient is as follows:

	Time	A%	B%	C%	D%	Flow	Curve
	0.00	0.0	0.0	100.0	0.0	1.000	1
	90.00	0.0	0.0	55.0	45.0	1.000	6
30	90.10	0.0	0.0	0.0	100.0	1.000	6
	91.00	0.0	0.0	0.0	100.0	1.000	6
	91.10	0.0	0.0	100.0	0.0	1.000	6
	95.00	0.0	0.0	100.0	0.0	1.000	6

The column is heated to 40°C using a heat jacket.
 Peaks were detected using a Waters 996 PDA detector
 collecting data between 210 and 300 nm. The extracted
 chromatogram at 214 nm was used for sample analysis to
 5 determine the extent of n-terminal Pegylation (loss of
 T-1 fragment) as shown in Table 2.

Table 2

Sample	% T-1 present	% T-1 Lost	%T-1 Present compared to control
Aldehyde			
5K ALD	2.0	98.0	7.4
20K	0.0	100.0	0.0
2x20K	0.0	100.0	0.0
30K	1.3	98.7	4.5
40K			
Branched	1.9	98.1	6.8
NHS			
4-6x5 SPA	1.3	98.7	4.7
2-4x5 CM	0.0	100.0	0.0
20K CM	23.1	76.9	84.1
30K	18.2	81.8	63.9
2x30K	5.7	94.3	19.9
40K			
branched	20.9	79.1	73.5

10 Example 20

Pharmacodynamic Studies

Efficacy studies in Hypophysectomized rats
 Female Sprague Dawley rats, hypophysectomized at
 15 Harlan Labs, were prescreened for growth rate for a
 period of 7 to 10 days. Subsequently, growth studies
 were carried out for 11 days. Rats were divided into
 groups of six to eight. Group 1 consisted of rats
 given either daily or day 0 and day 6 subcutaneous
 20 dose(s) of vehicle. Group 2 were given daily

subcutaneous doses of GH (0.3 mg/kg/dose). Group 3 were given subcutaneous doses of GH on day 0 and day 6 (1.8 mg/kg/dose). Group 4 were given subcutaneous doses of PEG-GHs on day 0,6 (1.8 mg/kg/dose).

- 5 Hypophysectomized rats were monitored for weight gain by weighing at least every other day during the study. Weight gains (average +/- SEM) for 20K PEG-ALD hGH, 20K and 40K branched PEG-ALD hGH, and 4-6x 5PEG-SPA hGH dosed once a week were similar to those for daily dosing of hGH (Figures 3& 4) Table 3 summarizes total weight gain (average +/- SEM) at day 11 for once per week dosing of various Pegylated hGH molecules relative to daily dosing of hGH.

15 Table 3
Murine weight gain

Compound	Single Weekly Dose (mpk)	Daily weight gain in grams/day (d0-d11) (Avg. + SEM)	% weight gain relative to daily hGH gain (Avg.)
hGH (un-pegylated)	1.8	0.97 + 0.12	39%
5K Linear PEG-ALD GH	1.8	0.96 + 0.27	36%
20K Linear PEG-ALD GH	1.8	1.99 + 0.13, 1.43 + 0.08, 1.7 + 0.10	73%
20K Linear CM-HBA PEG GH	1.8	2.36 + 0.11	99%
20K Linear PEG-HYD GH	1.8	2.62 + 0.22	99%
20K Branched PEG-ALD GH	1.8	2.24 + 0.07	87%
30K Linear PEG-ALD GH	1.8	2.11+ 0.06; 1.85+ 0.14	94%
30K Linear PEG-SPA GH	1.8	2.6 +/- 0.1	117%
40K Branched PEG-ALD GH	1.8	2.57 + 0.08	100%
40K Branched PEG-NHS GH	1.8	2.53 + 0.09	121%
2x 20K PEG-ALD GH	1.8	2.66 + 0.10	128%
4-6x5K SPA-PEG GH	1.8	3.18 + 0.10	124%
2-4x5K CM-HBA-PEG GH	1.8	3.54 + 0.15	134%
2x 30K Linear PEG-SPA GH	1.8	3.1 + 0.1	134%

- 20 Upon completion of each growth study, animals were sacrificed and bone (tibia) lengths were analyzed. Figure 6 shows the change in tibial bone length (average +/- SEM) at day 11 in response to various

PEG-GH conjugates dosed on day 0 and day 6 or hGH dosed daily.

IGF-1 levels in hypophysectomized rats

5

Experiments were carried out as above for the weight gain studies, however blood samples were taken at day 0,1,2,3,4,5 and upon sacrifice of the animals at day 9. IGF-1 levels were determined by ELISA. Figure 7
10 compares increases in serum IGF-1 levels (average +/- SEM) in hypophysectomized rats following either daily dosing of hGH or single dose of hGH or day 0, day 6 dosing of Pegylated hGH.

15 *Pharmacokinetic Studies*

Pharmacokinetic studies were conducted in normal, Sprague-Dawley male rats, mice, and cynomolgus monkeys. Injections were made, either as a single
20 subcutaneous bolus of 1.8 mg/kg or as a single iv dose at 1.0 mg/kg GH or PEG-GH in rats and mice, using six rats and up to 60 mice per group. In cynomolgus monkeys a 0.18 mg/kg GH or PEG-GH dose was used for both single subcutaneous bolus and iv, using 2-4
25 monkeys per group. Blood samples were taken over one to five days as appropriate for assessment of relevant PK parameters (Table 4). ($t_{1/2}$) = Terminal half life, (Cl) = clearance, (Tmax) = time to maximum concentration, Vss = volume distribution (apparent) at
30 steady state, and (Cmax) = maximum concentration GH and PEG-GH blood levels were monitored at each sampling using immuno-assay.

hGH Immunoassay

hGH and pegylated hGH protein concentration levels in rat, mouse, and cynomolgus monkey plasma were determined using the hGH AutoDELFIA kit fluorescence immunoassay (PerkinElmer Life Sciences),
5 using the appropriate PEG hGH to generate standard curve.

Table 4

Species	Parameters	40K Br ALD hGH	40K Br NHS hGH	30K ALD hGH	20K ALD hGH	4-6 x 5K SPA
mouse	dose (mg/kg)	iv 1.0 sc 1.8	iv 1.0 sc 1.8	iv 1.0 sc 1.8	iv 1.0 sc 1.0	iv 1.0 sc 1.8
	CL (ml/hr/kg)	2.29	2.12	4.43	7.89	4.53
	Vss (ml/kg)	18	16	24	17	51
	T _{1/2, iv} (hr)	4.3	3.8	2.8	1.8	11
	T _{1/2, sc} (hr)	4	6.2	3.7	2.5	9
	Tmax, sc (hr)	11	9	6	3	12
	SC AUC (ug/ml*hr)	682	577	160	31	668
	SC Bioavailability (%)	87	67	39	24	167
	dose (mg/kg)	iv 1.0 sc 1.8	iv 1.0 sc 1.8	iv 1.0 sc 1.8	iv 1.8 sc 1.8	iv 1.0 sc 1.8
	CL (ml/hr/kg)	1.36	1.75	5.75	9.9	2.9
rat	Vss (ml/kg)	19	25	44	33	36
	T _{1/2, iv} (hr)	5.4	5.8	3.6	2.2	24
	T _{1/2, sc} (hr)	5.8	7.1	6.7	2.9	29
	Tmax, sc (hr)	24	22	12	9	20
	SC AUC (ug/ml*hr)	398	344	97	70	249
	SC Bioavailability (%)	30	33	31	39	40
	dose (mg/kg)	iv 0.18 sc 0.18	iv 0.18 sc 0.18	iv 0.18 sc 0.18	iv 0.18 sc 0.18	iv 0.18 sc 0.18
	CL (ml/hr/kg)	1.83	0.78	1.94	2.19	0.49
	Vss (ml/kg)	57	20	29	44	25
	T _{1/2, iv} (hr)	21	13.6	14.9	7.3	38
cyno	T _{1/2, sc} (hr)	19	21	12	8.3	35
	Tmax, sc (hr)	22	22	10	8	32
	SC AUC (ug/ml*hr)	100	483	125	38	242
	SC Bioavailability (%)	64	77	97	44	66






WHAT IS CLAIMED IS:

1. A conjugate comprising at least one water-soluble polymer molecule covalently attached to at least one amino acid residue of a biologically active human growth hormone (hGH) polypeptide or agonist variant thereof.
2. The conjugate of claim 1 wherein said hGH polypeptide comprises the amino acid sequence of SEQ ID NO:1.
3. The conjugate of claim 1, or 2, wherein said polymer is a poly(ethylene oxide) molecule.
4. The conjugate of claim 3 wherein said poly(ethylene oxide) molecule is a poly(ethylene glycol) molecule.
5. The conjugate of claim 4 wherein the poly(ethylene glycol) is attached at an amino acid residue having a free amino group(s), carboxyl group(s), or sulfhydryl group(s).
6. The conjugate of claim 5 formed using a activated poly(ethylene glycol).
7. The conjugate of claim 6 wherein said activated poly(ethylene glycol) comprises a functional group.
8. The conjugate of claim 7 wherein said attachment is at an amino acid having a free amino group.

9. The conjugate of claim 8 wherein said functional group is selected from the group consisting of: carbonates, carbonyl imidazole, active esters of carboxylic acids, azlactones, cyclic imide thiones, isocyanates or isothiocyanates, imidates, and aldehydes.

10. The conjugate of claim 9 wherein said functional group is a carbonate or carbonyl imidazole.

11. The conjugate of claim 10 wherein said activated poly(ethylene glycol) is selected from the group consisting of:



15

12. The conjugate of claim 11 having the structure




20

wherein R is a human growth hormone polypeptide.

13. The conjugate of claim 12 wherein said human growth hormone polypeptide comprises the amino acid
5 sequence of SEQ ID NO:1.

14. The conjugate of claim 9 wherein said functional group is a cyclic imide thione.



10 15. The conjugate of claim 14 wherein said activated poly(ethylene glycol) is selected from the group consisting of:



15 wherein L is selected from the group consisting of: -O-, -NH-, -OCH₂-, -NH-CO(CH₂)_n-, -NH-CO(CH₂)_nO-, -CO-NH(CH₂)_n-, -S-, -CO-NH(CH₂)_nO-, -O(CH₂)_nO-, -O(CH₂)_n-, -SCH₂CH₂-, AND -NH(CH₂)_n-.

16. The conjugate of claim 9 wherein said functional group is a azlactone.

17. The conjugate of claim 16 wherein said
5 activated poly(ethylene glycol) is selected from the group consisting of:



10 wherein

R^1 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, carbocyclic and heterocyclic aromatic rings, α , β -unsaturated alkyl; and

15 R^2 and R^3 are independently selected from hydrogen, alkyl, aryl, and alkylaryl.

18. The conjugate of claim 9 wherein said functional group is a isocyanate or isothiocyanate.





20

19. The conjugate of claim 18 wherein said activated poly(ethylene glycol) is selected from the group consisting of:

25 mPEG-N=C=O, and mPEG-N=C=S.

20. The conjugate of claim 9 wherein said functional group is an aldehyde or aldehyde hydrate.


21. The conjugate of claim 20 wherein said
5 activated poly(ethylene glycol) is selected from the group consisting of:




15 22. The conjugate of claim 9 wherein said functional group is an active ester of a carboxylic acid.

23. The conjugate of claim 22 wherein said activated poly(ethylene glycol) is selected from the group consisting of:

5




24. The conjugate of claim 23 having the structure selected from the group consisting of:




wherein R is a human growth hormone polypeptide.

25. The conjugate of claim 24 wherein said human growth hormone polypeptide comprises the amino acid sequence of SEQ ID NO:1.

26. The conjugate of claim 9 wherein said activated poly(ethylene glycol) is selected from the group consisting of:



27. The conjugate of claim 26 having the structure selected from the group consisting of:



PEG-NH-R, and

5

wherein R is a human growth hormone polypeptide.


28. The conjugate of claim 27 wherein said human growth hormone polypeptide comprises the amino acid sequence of SEQ ID NO:1.

10


29. The conjugate of claim 28 wherein said functional group is an imidate.

15

30. The conjugate of claim 9 wherein said activated poly(ethylene glycol) is selected from the group consisting of:



wherein m is 0 to 20, and



wherein R¹ is alkyl, phenyl, phenylalkyl, and cycloalkyl.

20

31. The conjugate of claim 9 wherein said free amino group is an amino terminal α-amino group.

32. The conjugate of claim 31 wherein said amino terminal α-amino group is on a phenylalanine.

25

33. The conjugate of claim 8 wherein said attachment is at an amino acid having a free carboxyl group.

5


34. The conjugate of claim 33 wherein said functional group is selected from the group consisting of: primary amines; hydrazine; and hydrazide functional groups.

10

35. The conjugate of claim 34 wherein said functional group is selected from the group consisting of:

15

mPEG-CH₂CH₂-NH₂, mPEG-O-CH₂-CO-NH-NH₂,





36. The conjugate of claim 8 wherein said attachment is at an amino acid having a free sulfhydryl group.



20

37. The conjugate of claim 36 wherein said functional group is selected from the group consisting of: thiols; maleimides; vinyl sulfones; and phenyl glyoxals.

38. The conjugate of claim 37 wherein said functional group is selected from the group consisting of:



39. The conjugate of claim 38 having the structure selected from the group consisting of:



wherein R is a human growth hormone polypeptide.


40. The conjugate of claim 39 wherein said human growth hormone polypeptide comprises the amino acid sequence of SEQ ID NO:1.

5 41. The conjugate of claim 8 wherein said poly(ethylene glycol) has a molecular weight of between about 0.5 kDa and about 100 kDa.

10 42. The conjugate of claim 41 wherein said poly(ethylene glycol) has a molecular weight of between about 5 kDa and about 40 kDa.


15 43. The conjugate of claim 8 wherein said poly(ethylene glycol) is a branched polymer.

 44. The conjugate of claim 43 wherein said branched polymer is selected from the group consisting of:



45. A human growth hormone-PEG conjugate having the structure

5



wherein R is a human growth hormone polypeptide.


46. The conjugate of claim 45 wherein said human growth hormone polypeptide comprises the amino acid sequence of SEQ ID NO:1.

5 47. The conjugate of claim 46 wherein at least 80% of said polyethylene glycol is conjugated to the amino-terminal phenylalanine.

10 48 The conjugate of claim 46 wherein at least 90% of said polyethylene glycol is conjugated to the amino-terminal phenylalanine.

15 49. The conjugate of claim 47 or 48 wherein each mPEG has a molecular weight of about 20 kDa.

50. A human growth hormone-PEG conjugate having the structure



20

wherein R is a human growth hormone polypeptide.

25 51. The conjugate of claim 50 wherein said human growth hormone polypeptide comprises the amino acid sequence of SEQ ID NO:1.


52. The conjugate of claim 51 wherein at least 80% of said polyethylene glycol is conjugated to the amino-terminal phenylalanine.

53. The conjugate of claim 51 wherein at least 90% of said polyethylene glycol is conjugated to the amino-terminal phenylalanine.

5

54. The conjugate of claim 52 or 53 wherein each mPEG has a molecular weight of about 20 kDa.

55. A human growth hormone-PEG conjugate having
10 the structure



wherein R is a human growth hormone polypeptide.
15

56. The conjugate of claim 55 wherein said human growth hormone polypeptide comprises the amino acid sequence of SEQ ID NO:1.

20 57. The conjugate of claim 56 wherein at least 80% of said polyethylene glycol is conjugated to the amino-terminal phenylalanine.

58. The conjugate of claim 56 wherein at least
25 90% of said polyethylene glycol is conjugated to the amino-terminal phenylalanine.

59. The conjugate of claim 57 or 58 wherein each mPEG has a molecular weight of about 20 kDa.
30

60. The conjugate of claim 8 wherein said poly(ethylene glycol) is a bifunctional polymer.

61. The conjugate of claim 8 wherein said
35 poly(ethylene glycol) is a prodrug.

62. A composition comprising the hGH of claim 1 and at least one pharmaceutically acceptable carrier.

5 63. A method of treating a patient having a growth or development disorder or comprising administering to said patient a therapeutically effective amount of the hGH conjugate of claim 1.

10 64. The method of claim 63 wherein said growth or development disorder is Growth Hormone Deficiency (GHD).

15 65. The method of claim 63 wherein said growth or development disorder is Turner's syndrome.

20 66. The method of claim 63 wherein said growth or development disorder is Chronic Renal Insufficiency.

20 67. The method of claim 63 wherein said growth or development disorder is small for gestational age (SGA).

25 68. A composition comprising the hGH of claim 48 and at least one pharmaceutically acceptable carrier.

30 69. A method of treating a patient having a growth or development disorder or comprising administering to said patient a therapeutically effective amount of the hGH conjugate of claim 48.

35 70. The method of claim 69 wherein said growth or development disorder is Growth Hormone Deficiency (GHD).

71. The method of claim 69 wherein said growth or development disorder is Turner's syndrome.

72. The method of claim 69 wherein said growth
5 or development disorder is Chronic Renal Insufficiency.

73. The method of claim 69 wherein said growth or development disorder is small for gestational age
10 (SGA).

74. A composition comprising the hGH of claim 50 or 55 and at least one pharmaceutically acceptable carrier.
15

75. A method of treating a patient having a growth or development disorder or comprising administering to said patient a therapeutically effective amount of the hGH conjugate of claim 1.
20

76. The method of claim 75 wherein said growth or development disorder is Growth Hormone Deficiency (GHD).

25 77. The method of claim 75 wherein said growth or development disorder is Turner's syndrome.

78. The method of claim 75 wherein said growth or development disorder is Chronic Renal
30 Insufficiency.

79. The method of claim 75 wherein said growth or development disorder is small for gestational age (SGA).

Figure 1




Figure 2





Figure 3

Figure 4




Figure 5




Figure 6




Figure 7





Figure 8



03582_1_PCT.ST25.txt
SEQUENCE LISTING

<110> Pharmacia Corporation

Finn, Rory

Liao, Wei

Siegel, Ned

<120> CHEMICALLY-MODIFIED HUMAN GROWTH HORMONE CONJUGATES

<130> 03582/1/PCT

<150> US 60/331907

<151> 2001-11-20

<160> 1

<170> PatentIn version 3.1

<210> 1

<211> 191

<212> PRT

<213> homo sapiens

<400> 1

Phe	Pro	Thr	Ile	Pro	Leu	Ser	Arg	Leu	Phe	Asp	Asp	Ala	Met	Leu	Arg
1				5				10					15		

Ala	His	Arg	Leu	His	Gln	Leu	Ala	Phe	Asp	Thr	Tyr	Gln	Glu	Phe	Glu
			20					25					30		

Glu	Ala	Tyr	Ile	Pro	Lys	Glu	Gln	Lys	Tyr	Ser	Phe	Leu	Gln	Asp	Pro
		35					40					45			

Gln	Thr	Ser	Leu	Cys	Phe	Ser	Glu	Ser	Ile	Pro	Thr	Pro	Ser	Asp	Arg
	50					55					60				

03582_1_PCT.ST25.txt

Glu Glu Thr Gln Gln Lys Ser Asp Leu Glu Leu Leu Arg Ile Ser Leu
65 70 75 80

Leu Leu Ile Gln Ser Trp Leu Glu Pro Val Gln Ser Leu Arg Ser Val
85 90 95

Phe Ala Asp Ser Leu Val Tyr Gly Ala Ser Asp Ser Asp Val Tyr Asp
100 105 110

Leu Leu Lys Asp Leu Glu Glu Gly Ile Gln Thr Leu Met Gly Arg Leu
115 120 125

Glu Asp Gly Ser Pro Arg Thr Gly Gln Ile Phe Lys Gln Thr Tyr Ser
130 135 140

Lys Phe Asp Thr Asp Ser His Asp Asp Ala Leu Leu Lys Asp Tyr
145 150 155 160

Gly Leu Leu Tyr Cys Phe Arg Lys Asp Met Asp Lys Val Glu Thr Phe
165 170 175

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe
180 185 190

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 03/044056 A3

(51) International Patent Classification⁷: **C07K 14/61**,
A61K 47/48, 38/27

(21) International Application Number: PCT/US02/37270

(22) International Filing Date:
20 November 2002 (20.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/331,907 20 November 2001 (20.11.2001) US

(71) Applicant (for all designated States except US): **PHARMACIA CORPORATION** [US/US]; Corporate Patent Dept., P.O. Box 1027, St. Louis, MO 63006 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **Box Rory, F.** [US/US]; 976 Sunnburst Ct., Manchester, MO 63021 (US). **LAO, Wei** [CN/US]; 17143 Hillcrest Meadow Drive, Chesterfield, MO 63005 (US). **SIEGEL, Ned, R.** [US/US]; 312 North Powder Mill Rd., Belleville, IL 62223 (US).

(74) Agents: **BAUER, Christopher, S.** et al.; Pharmacia Corporation, Corporate Patent Department, 800 North Lindbergh Blvd., Mailzone O4E, St Louis, MO 63167 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
21 August 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICALLY-MODIFIED HUMAN GROWTH HORMONE CONJUGATES

(57) Abstract: The present invention provides a chemically modified human Growth Hormone (hGH) prepared by binding a water soluble polymer to the protein. The chemically-modified protein according to the present invention may have a much longer lasting hGH activity than that of the unmodified hGH, enabling reduced dose and scheduling opportunities.

WO 03/044056 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/37270

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/61 A61K47/48 A61K38/27

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 02 055532 A (CHRISTIANSEN JESPER ;MAXYGEN APS (DK); DRUSTRUP JOERN (DK); ANDERS) 18 July 2002 (2002-07-18) the whole document	1-79
Y	VERONESE FRANCESCO M: "Peptide and protein PEGylation: A review of problems and solutions." BIOMATERIALS, vol. 22, no. 5, March 2001 (2001-03), pages 405-417, XP002237938 ISSN: 0142-9612 the whole document	1-79



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

10 April 2003

Date of mailing of the international search report

05.05.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/37270

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01 76639 A (FINN RORY ; QI HONG (US); SEDO KURT (US); GOKARN YATIN (US); HILLS) 18 October 2001 (2001-10-18) examples the whole document ---	1-79
X	US 4 179 337 A (DAVIS FRANK F ET AL) 18 December 1979 (1979-12-18) column 3 the whole document ---	1-35, 41-79
Y	the whole document ---	1-79
X	WO 97 11178 A (GENENTECH INC ; OLSON KENNETH (US); WELLS JAMES A (US); CLARK ROSS) 27 March 1997 (1997-03-27) cited in the application page 47 -page 51; examples VII-XIV ---	1-32, 41-79
Y	page 47 -page 51; examples VII-XIV ---	1-79
X	CLARK R ET AL: "Long-acting growth hormones produced by conjugation with polyethylene glycol" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 36, 6 September 1996 (1996-09-06), pages 21969-21977, XP002216386 ISSN: 0021-9258 the whole document ---	1-32, 41-79
Y	the whole document ---	1-79
X	WO 93 00109 A (GENENTECH INC) 7 January 1993 (1993-01-07) cited in the application page 3 page 20 ---	1-32, 41-79
Y	page 3 page 20 ---	1-79
Y	WO 96 11953 A (AMGEN INC) 25 April 1996 (1996-04-25) page 7 ---	1-32, 41-79
Y	WO 00 44785 A (HOFFMANN LA ROCHE) 3 August 2000 (2000-08-03) page 26 ---	1-32, 41-79
Y	WO 89 05824 A (GENETICS INST) 29 June 1989 (1989-06-29) page 10 -page 11 ---	1-32, 41-79
X	WO 00 42175 A (COX GEORGE N ; BOLDER BIOTECHNOLOGY INC (US); DOHERTY DANIEL H (US)) 20 July 2000 (2000-07-20) cited in the application the whole document ---	36-40
Y	the whole document ---	1-79

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/37270

C₁(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 03887 A (BOLDER BIOTECHNOLOGY INC ;COX GEORGE N III (US)) 28 January 1999 (1999-01-28)	36-40
Y	the whole document ---	1-79
X	EP 0 458 064 A (AMERICAN CYANAMID CO) 27 November 1991 (1991-11-27)	36-40
Y	the whole document ---	1-79
X	WO 92 16555 A (ENZON INC) 1 October 1992 (1992-10-01) the whole document page 7, line 28 ---	33-35
Y	ZALIPSKY S: "FUNCTIONALIZED POLY(ETHYLENE GLYCOL) FOR PREPARATION OF BIOLOGICALLY RELEVANT CONJUGATES" BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 6, no. 2, 1995, pages 150-165, XP002068523 ISSN: 1043-1802 the whole document page 153 ---	1-79
Y	MONFARDINI C ET AL: "A BRANCHED MONOMETHOXYPOLY(ETHYLENE GLYCOL) FOR PROTEIN MODIFICATION" BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 6, no. 1, 1995, pages 62-69, XP000494804 ISSN: 1043-1802 the whole document ---	1-32, 41-79
X	THORNER MICHAEL O ET AL: "Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH." JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 84, no. 6, June 1999 (1999-06), pages 2098-2103, XP002237939 ISSN: 0021-972X	1-7, 62-67, 75-79
Y	the whole document ---	1-79
Y	EP 0 605 963 A (ORTHO PHARMA CORP) 13 July 1994 (1994-07-13) the whole document ---	1-79
	--- -/--	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/37270

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>FELIX A M ET AL: "PEGYLATED PEPTIDES IV ENHANCED BIOLOGICAL ACTIVITY OF SITE-DIRECTED PEGYLATED GRF ANALOGS" INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, MUNKSGAARD, COPENHAGEN, DK, vol. 46, no. 3/4, 1 September 1995 (1995-09-01), pages 253-264, XP000526320 ISSN: 0367-8377 the whole document</p> <p>-----</p>	1-79

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 02/37270

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 63-67, 69-73, 75-79 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 8-32,41-61,68-74(all complete);1-7,62-67,75-79(all in part)

Human growth hormone-PEG conjugates wherein the hGH-PEG attachment is at an amino acid having a free amino group.
Uses for treatment of growth or development disorders

2. Claims: 33-35(all complete);1-7,62-67,75-79(all in part)

Human growth hormone-PEG conjugates wherein the hGH-PEG attachment is at an amino acid having a free carboxyl group.
Uses for treatment of growth or development disorders

3. Claims: 36-40(all complete);1-7,62-67,75-79(all in part)

Human growth hormone-PEG conjugates wherein the hGH-PEG attachment is at an amino acid having a free sulfhydryl group. Uses for treatment of growth or development disorders.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/37270

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02055532	A	18-07-2002	WO 02055532 A2	18-07-2002
WO 0176639	A	18-10-2001	AU 8930701 A	23-10-2001
			WO 0176639 A2	18-10-2001
US 4179337	A	18-12-1979	CA 1033673 A1	27-06-1978
			CH 616942 A5	30-04-1980
			DE 2433883 A1	05-02-1976
			FR 2313939 A1	07-01-1977
			GB 1469472 A	06-04-1977
			JP 1152589 C	30-06-1983
			JP 50042087 A	16-04-1975
			JP 56023587 B	01-06-1981
			NL 7409770 A	22-01-1975
			SE 441753 B	04-11-1985
			SE 7409366 A	21-01-1975
WO 9711178	A	27-03-1997	AU 718439 B2	13-04-2000
			AU 7073396 A	09-04-1997
			EP 0851925 A1	08-07-1998
			JP 11512298 T	26-10-1999
			US 6057292 A	02-05-2000
			US 6004931 A	21-12-1999
			US 6136563 A	24-10-2000
			WO 9711178 A1	27-03-1997
			US 5849535 A	15-12-1998
			ZA 9607973 A	23-06-1997
WO 9300109	A	07-01-1993	AU 2147192 A	25-01-1993
			PT 100629 A	30-09-1993
			WO 9300109 A1	07-01-1993
WO 9611953	A	25-04-1996	US 5824784 A	20-10-1998
			AT 179991 T	15-05-1999
			AU 706700 B2	24-06-1999
			AU 1841995 A	06-05-1996
			AU 4887099 A	11-11-1999
			CA 2178752 A1	25-04-1996
			CA 2307142 A1	25-04-1996
			CN 1313343 A	19-09-2001
			CN 1139932 A , B	08-01-1997
			DE 69509628 D1	17-06-1999
			DE 69509628 T2	16-09-1999
			DK 733067 T3	01-11-1999
			EP 0733067 A1	25-09-1996
			EP 0822199 A2	04-02-1998
			ES 2131811 T3	01-08-1999
			GR 3030526 T3	29-10-1999
			HK 1008826 A1	31-03-2000
			IL 112585 A	31-08-2000
			JP 11310600 A	09-11-1999
			JP 3177449 B2	18-06-2001
			JP 9025298 A	28-01-1997
			JP 9506116 T	17-06-1997
			JP 3177251 B2	18-06-2001
			KR 248111 B1	15-03-2000
			KR 261030 B1	15-06-2000
			NZ 281469 A	24-04-1997

Form PCT/ISA/210 (patent family annex) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/37270

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9611953 A		WO 9611953 A1	25-04-1996
		US 5985265 A	16-11-1999
		ZA 9501008 A	18-10-1996
WO 0044785 A	03-08-2000	AU 2618500 A	18-08-2000
		BG 105851 A	28-06-2002
		BR 0007781 A	05-02-2002
		CN 1376164 T	23-10-2002
		CZ 20012654 A3	15-05-2002
		EP 1157037 A1	28-11-2001
		JP 2002540065 T	26-11-2002
		SK 10352001 A3	04-06-2002
		WO 0044785 A1	03-08-2000
WO 8905824 A	29-06-1989	US 4904584 A	27-02-1990
		AU 2911189 A	19-07-1989
		EP 0355142 A1	28-02-1990
		JP 2502646 T	23-08-1990
		WO 8905824 A1	29-06-1989
WO 0042175 A	20-07-2000	AU 2413300 A	01-08-2000
		BR 0008759 A	06-08-2002
		CA 2359345 A1	20-07-2000
		CN 1355842 T	26-06-2002
		EP 1144613 A1	17-10-2001
		JP 2002534119 T	15-10-2002
		WO 0042175 A1	20-07-2000
WO 9903887 A	28-01-1999	AU 751898 B2	29-08-2002
		AU 8300098 A	10-02-1999
		BR 9812267 A	18-12-2001
		CN 1269805 T	11-10-2000
		EP 1012184 A1	28-06-2000
		JP 2001510033 T	31-07-2001
		NZ 502375 A	30-11-2001
		WO 9903887 A1	28-01-1999
EP 0458064 A	27-11-1991	AT 163431 T	15-03-1998
		AU 639324 B2	22-07-1993
		AU 7607591 A	07-11-1991
		CA 2041742 A1	05-11-1991
		DE 69128944 D1	02-04-1998
		DE 69128944 T2	25-06-1998
		DK 458064 T3	27-04-1998
		EP 0458064 A2	27-11-1991
		ES 2113354 T3	01-05-1998
		FI 912144 A	05-11-1991
		GR 3026436 T3	30-06-1998
		IE 911511 A1	06-11-1991
		IL 97932 A	22-02-1998
		JP 6009696 A	18-01-1994
		KR 213455 B1	02-08-1999
		NO 911752 A	05-11-1991
		NZ 237959 A	26-05-1994
		PT 97539 A ,B	28-02-1992
		US 5951972 A	14-09-1999
		US 6010999 A	04-01-2000
		ZA 9103359 A	25-03-1992

Form PCT/ISA/210 (patent family annex) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/37270

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9216555	A	01-10-1992	AU 1676992 A	21-10-1992
			CA 2101918 A1	19-09-1992
			EP 0576589 A1	05-01-1994
			JP 6506217 T	14-07-1994
			WO 9216555 A1	01-10-1992
<hr/>				
EP 0605963	A	13-07-1994	AU 5238393 A	23-06-1994
			EP 0605963 A2	13-07-1994
			FI 935485 A	10-06-1994
			JP 7196925 A	01-08-1995
			KR 254650 B1	01-05-2000
			KR 257643 B1	15-05-2000
			NO 934477 A	10-06-1994
			NZ 250375 A	26-07-1995
			CA 2110543 A1	10-06-1994
			ZA 9309214 A	08-06-1995

Form PCT/ISA/210 (patent family annex) (July 1992)